Skip to main content

SPONSORED CONTENT: Launching cGMP Manufacturing for Nanoformed APIs

1st December 2019

Submitted by:

Andrew Warmington

The innovative medicine-enabling nanotechnology company, Nanoform, discusses the construction of its first GMP manufacturing facility for the manufacture of nanonised drug particles.

This year has seen a rapid expansion of Nanoform’s manufacturing capabilities, through the construction of a state-of-the-art GMP plant. The facility will significantly increase the company’s capacity to handle potent APIs in development and also provide capability to scale up their production in a GMP environment, thus enabling nanonised materials for clinical trials and/or commercial use.

By achieving GMP Class D standards in this first facility, Nanoform will be able to handle potent APIs down to 1 µg/m3 OEL levels. This facility will also be the first in the world to manufacture GMP API particles smaller than 100nm and on occasion in the 10nm range.

Christian Jones, CCO of Nanoform, comments: “Nanoform are leading the drive towards more effective medicines by designing and producing best-in-class drug nanoparticles through our proprietary CESS® Nanonization™ technology.”

“This is the first major step for Nanoform in enabling novel R&D solutions developed by our teams to be transformed into quality GMP deliverables for our partners. It cements our position in the pharmaceutical marketplace as the ‘go-to’ experts for solubility and bioavailability enhancement and novel drug delivery applications. Further expansions are also planned to meet the significant and growing demand we see from the marketplace.

“Nanoform will deliver manufacturability assessments to provide continual and iterative process improvements for their partners. Dr David Rowe, who was appointed Head of Manufacturing this year, says: “This will ensure a best-in-class drug development process, from entry of the drug compound into the facility through to launch”

David Rowe has extensive experience proving technical leadership and strategic technical direction for both new chemical entities and commercial assets. He has deep scientific knowledge of particle size reduction platforms and the efficient commercial manufacturability of new products globally, having previously worked as the Global Particle Size Reduction Lead for GlaxoSmithKline.

Dr Rowe is now responsible for directing and implementing technical strategies and operational plans at Nanoform, which will ensure efficient commercial manufacturability of new products. The combination of a strengthened manufacturing organisation and increased capacity will enable a significant increase in the number of new drugs reaching the market.

Find out more at Nanoform.com

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington